Canada markets closed
  • S&P/TSX

    19,779.97
    -11.63 (-0.06%)
     
  • S&P 500

    4,320.06
    -9.94 (-0.23%)
     
  • DOW

    33,963.84
    -106.56 (-0.31%)
     
  • CAD/USD

    0.7417
    -0.0002 (-0.03%)
     
  • CRUDE OIL

    90.33
    +0.70 (+0.78%)
     
  • Bitcoin CAD

    35,958.02
    +72.02 (+0.20%)
     
  • CMC Crypto 200

    565.87
    -2.18 (-0.38%)
     
  • GOLD FUTURES

    1,944.90
    +5.30 (+0.27%)
     
  • RUSSELL 2000

    1,776.50
    -5.33 (-0.30%)
     
  • 10-Yr Bond

    4.4380
    -0.0420 (-0.94%)
     
  • NASDAQ

    13,211.81
    -12.19 (-0.09%)
     
  • VOLATILITY

    17.20
    -0.34 (-1.94%)
     
  • FTSE

    7,683.91
    +5.29 (+0.07%)
     
  • NIKKEI 225

    32,402.41
    -168.59 (-0.52%)
     
  • CAD/EUR

    0.6965
    +0.0008 (+0.11%)
     

Pfizer's Heading for a Patent Cliff. Is the Stock Still a Buy?

Pfizer's Heading for a Patent Cliff. Is the Stock Still a Buy?

The company also continues to benefit from sales of blockbusters including blood thinner Eliquis and oncology drug Ibrance. In fact, Pfizer expects patent losses alone to lead to $17 billion in lost revenue from 2025 through 2030. In spite of these upcoming obstacles, is Pfizer still a buy?